Clinical Trial Update: Pilot Study of Raptiva to Treat Sjogren's Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 pilot study evaluating efalizumab (Raptiva) for Sjögren's syndrome was terminated, with results posted in December 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Sjogren's Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2015-12-21